Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report-Reference-Cited by-同舟云学术

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report

Published:2019-03-06 Issue:5 Volume:7 Page:616-622
ISSN:2307-8960
Container-title:World Journal of Clinical Cases
language:
Short-container-title:WJCC

Author:

Thinn Mie Mie,Hsueh Chung-Tzu,Hsueh Chung-Tsen

Publisher

Baishideng Publishing Group Inc.

Subject

General Medicine

Reference18 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment

3. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584

4. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival

5. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials;Medical Oncology;2024-06-12

2. Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review;Oncology Letters;2023-09-27

3. RTKs in pathobiology of head and neck cancers;Advances in Cancer Research;2020

4. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation;Cell Communication and Signaling;2019-12